FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

White Mark K.
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/28/2020 

3. Issuer Name and Ticker or Trading Symbol

Annovis Bio, Inc. [ANVS]
(Last)        (First)        (Middle)

C/O ANNOVIS BIO, INC., 1055 WESTLAKES DRIVE, SUITE 300
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

BERWYN, PA 19312      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Convertible Note  (1) (1)Common Stock  (1) (1)D  
Series A-1 Preferred Stock  (2) (2)Common Stock 11548  (2)D  
Series A Preferred Stock  (3) (3)Common Stock 34643  (3)D  
Stock Option (right to buy)  (4)4/7/2026 Common Stock 14284 $0.14 D  
Stock Option (right to buy)  (4)4/7/2026 Common Stock 7142 $0.25 D  

Explanation of Responses:
(1) The Convertible Notes have a maturity date of December 31, 2023. Prior to the maturity date, the Convertible Notes will automatically convert into common stock of Annovis Bio, Inc. ("Annovis") upon an initial public offering ("IPO") of Annovis at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by 80% of the public offering price per share of the IPO as set forth on the cover page of the final prospectus for the IPO.
(2) Each share of Series A-1 Preferred Stock is convertible into common stock of Annovis and has no expiration date. Upon the closing of the IPO, 16,167 shares of Series A-1 Preferred Stock, along with the aggregate accrued or accumulated and unpaid dividends thereon, will automatically be converted into 11,548 shares of common stock of Annovis.
(3) Each share of Series A Preferred Stock is convertible into common stock of Annovis and has no expiration date. Upon the closing of the IPO, 48,500 shares of Series A Preferred Stock, along with the aggregate accrued or accumulated and unpaid dividends thereon, will automatically be converted into 34,643 shares of common stock of Annovis.
(4) As of the date of this report, all of the shares underlying the options are fully vested and exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
White Mark K.
C/O ANNOVIS BIO, INC.
1055 WESTLAKES DRIVE, SUITE 300
BERWYN, PA 19312
X



Signatures
/s/ Maria Maccecchini Attorney-in-Fact1/29/2020
**Signature of Reporting PersonDate


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.